Memory Pharma Completes Enrollment in Alzheimer's Disease Study

Memory Pharmaceuticals announced it has completed enrollment in its Phase IIa trial of MEM 1003 in Alzheimer's disease. The company expects to report top-line results for this trial in the fourth quarter of 2007.

This trial is a multicenter, randomized, double-blind, placebo-controlled study to evaluate the safety and efficacy of two dose levels of MEM 1003 in approximately 180 subjects with mild to moderate Alzheimer's disease at more than 50 centers in the U.S. Subjects participating in the study were randomized at enrollment into one of three treatment groups: 30 mg of MEM 1003 twice a day, 90 mg of MEM 1003 twice a day or placebo twice a day.

During the double-blind treatment segment of the study, subjects receive MEM 1003 or placebo for a period of 12 weeks, which is followed by a four-week, single-blind placebo treatment period. The primary outcome measure of the trial is a 12-week change in the Alzheimer's Disease Assessment Scale Cognitive subscale score. Secondary measures will assess changes in activities of daily living, behavior and global function.

MEM 1003 is a neuronal L-type calcium channel modulator. By blocking L-type calcium channels, the drug may regulate the flow of calcium and reestablish normal levels of calcium, which may help treat and prevent the onset of Alzheimer's disease, according to the company.